/ /

  • linkedin
  • Increase Font
  • Sharebar

    Topical drops show promise as treatment for presbyopia

    Agent allowed a ‘dynamic’ pupil and was without significant adverse effects

    Take-home message: In a prospective study including 20 presbyopic emmetropes, treatment with a proprietary topical ophthalmic formulation (PresbV Tears) demonstrated benefit for improving near, intermediate, and far uncorrected visual acuity.



    Popayán, Colombia—Results of a prospective study show that treatment with a proprietary topical ophthalmic formulation (PresbV Tears) safely and effectively increases physiological accommodation to improve uncorrected near and intermediate vision without compromising distance vision in presbyopic emmetropes, said its inventor, Luis Felipe Vejarano, MD.

    “This topical agent represents a noninvasive solution for addressing presbyopia that I believe meets all of the criteria for an ideal treatment,” said Dr. Vejarano, associate professor of ophthalmology, University of Cauca, Popayán, Colombia. “It is binocular, truly accommodative, improves near, intermediate, and far vision or at least doesn´t alter it, and allows a dynamic pupil in different light conditions (“dynamic pseudoaccommodation”) that could also diminish glare and avoid decrease in contrast sensitivity.”

    Dr. Vejarano

    In addition, it is, non–toxic, causing no adverse effects on the lacrimal film, corneal epithelium or endothelial cells, macula, or trabecular meshwork, he noted.

    “My personal experience using it for more than 5 years and the outcomes of patients treated in a prospective study show that it enables spectacle independence for most activities and does so without significant risks or side effects,” Dr. Vejarano said.

    About the study

    The study enrolled 20 patients, of whom 9 were natural emmetropes and 11 had a history of LASIK (6 using the Vejarano Method for Presbyopia). The patients ranged in age from 41 to 57 years with a mean of about 50 years.

    Assessments for efficacy and safety were performed prior to instillation of a single drop in each eye and after 0.5, 1, 2, 3, 4, and 5 hours, 7 and 30 days.

    “Although this study was designed to assess the efficacy and safety after using a single drop in each eye, the topical formulation is intended to be used twice daily, once in the morning and once in the afternoon,” Dr. Vejarano said.

    The results showed near uncorrected visual acuity (UCVA) improved by about 2 to 3 lines in each eye and binocularly from a baseline mean of about J3.5 to about J1.5. Mean UCVA at far was 20/25 at baseline, and except for a slight decrease after 1 hour, was improved by an average of about 1 line in each eye at all follow-up measurements. Binocularly, UCVA at far increased by 1 line on average, and no patient had a loss in binocular UCVA at far.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results